CNS Drugs (2018) 32:399–400
https://doi.org/10.1007/s40263-018-0510-z

AUTHOR CORRECTION

Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease

Lawrence W. Elmer[1] · Jorge L. Juncos[2] · Carlos Singer[3] · Daniel D. Truong[4] · Susan R. Criswell[5] · Sotirios Parashos[6] · Larissa Felt[7] · Reed Johnson[7] · Rajiv Patni[7]

Published online: 10 April 2018

Author Correction to: CNS Drugs https://doi.org/10.1007/s40263-018-0498-4

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted:

Table 2, Primary efficacy results for the phase III studies and pooled populations at week 12: in the 'Pooled' section of the table, the 'Placebo' and 'ADS-5102' column headings are transposed. The corrected table is shown in the following page.

The original article has been corrected.

The original article can be found online at https://doi.org/10.1007/s40263-018-0498-4.

✉ Lawrence W. Elmer
Lawrence.Elmer@utoledo.edu

[1] Department of Neurology, University of Toledo College of Medicine, 3120 Glendale Avenue, Toledo, OH 43614, USA

[2] Department of Neurology and Movement Disorders, Emory University School of Medicine, Atlanta, GA, USA

[3] Department of Neurology, University of Miami, Miami, FL, USA

[4] The Parkinson's and Movement Disorder Institute, Fountain Valley, CA, USA

[5] Department of Neurology, Washington University, St. Louis, MO, USA

[6] Struthers Parkinson's Center, Golden Valley, MN, USA

[7] Adamas Pharmaceuticals, Inc., Emeryville, CA, USA

Table 2 Primary efficacy results for the phase III studies and pooled populations at week 12

Parameter	EASE LID				EASE LID 3				Pooled			
	LS mean change from baseline (SE)				LS mean change from baseline (SE)				LS mean change from baseline (SE)			
	ADS-5102 [n = 63]	Placebo [n = 58]	Treatment difference[a] [95% CI]	p value[b]	ADS-5102 [n = 37]	Placebo [n = 38]	Treatment difference[a] [95% CI]	p value[b]	ADS-5102 [n = 100]	Placebo [n = 96]	Treatment difference[a] [95% CI]	p value[b]
UDysRS total score, absolute	− 15.9 (1.6)	− 8.0 (1.6)	− 7.9 (− 12.5, − 3.3)	0.0009	− 20.7 (2.2)	− 6.3 (2.1)	− 14.4 (− 20.4, − 8.3)	< 0.0001	− 17.7 (1.3)	− 7.6 (1.3)	− 10.1 (− 13.8, − 6.5)	< 0.0001
UDysRS total score, relative, %	− 37.0 (5.8)	− 11.6 (5.9)	− 25.4 (− 41.7, − 9.0)	0.0027	− 45.8 (5.2)	− 16.3 (4.9)	− 29.6 (− 43.9, − 15.3)	< 0.0001	− 41.1 (4.2)	− 13.9 (4.1)	− 27.3 (− 38.7, − 15.8)	< 0.0001
UDysRS historical score (Parts I and II)	− 9.9 (1.0)	− 5.4 (1.0)	− 4.5 (− 7.4, − 1.6)	0.0027	− 12.1 (1.5)	− 4.0 (1.4)	− 8.1 (− 12.1, − 4.1)	0.0001	− 10.7 (0.86)	− 5.1 (0.84)	− 5.6 (− 8.0, − 3.3)	< 0.0001
UDysRS objective score (Parts III and IV)	− 6.1 (0.9)	− 2.7 (1.0)	− 3.4 (− 6.1, − 0.8)	0.0120	− 8.7 (1.3)	− 2.2 (1.2)	− 6.5 (− 10.1, − 3.0)	0.0004	− 7.0 (0.76)	− 2.5 (0.75)	− 4.5 (− 6.6, − 2.4)	< 0.0001

CI confidence interval, *LS* least squares, *SE* standard error, *UDysRS* Unified Dyskinesia Rating Scale

[a]ADS-5102–placebo

[b]*P* values are based on the comparison of ADS-5102 versus placebo from the mixed effect model repeat measurement model